Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.

Zhu, Lipeng; Li, Junnan; Guo, Ziang; Kwok, Hang Fai; Zhao, Qi

Zhu, Lipeng; Li, Junnan; Guo, Ziang; Kwok, Hang Fai; Zhao, Qi.

Afiliação

Zhu L; School of Life Sciences, Xiangya School of Medicine, Central South University, Changsha, 510006, China. zhuleaper@csu.edu.cn.
Li J; Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Guo Z; Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Kwok HF; Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
Zhao Q; Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. qizhao@um.edu.mo.

J Nanobiotechnology ; 20(1): 521, 2022 Dec 10.

Article em En | MEDLINE | ID: mdl-36496381

Assuntos

Neoplasias; Anticorpos de Domínio Único; Humanos; Imunoterapia; Ativação Linfocitária; Linfócitos T; Neoplasias/terapia; Neoplasias/metabolismo; Doxorrubicina/farmacologia; Linhagem Celular Tumoral; Microambiente Tumoral

Palavras-chave

Anti-PD-L1 nanobody; Hypoxia modulation; Immune-cold tumors; Immunogenic cell death; Nano-nuclear-reactor; T cell immune activation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos de Domínio Único / Neoplasias Limite: Humans Idioma: En Revista: J Nanobiotechnology Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google